BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29223453)

  • 1. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis.
    Moghoofei M; Mostafaei S; Ashraf-Ganjouei A; Kavosi H; Mahmoudi M
    Microb Pathog; 2018 Jan; 114():436-443. PubMed ID: 29223453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients.
    Schwaneck EC; Krone M; Kreissl-Kemmer S; Weißbrich B; Weiss J; Tony HP; Gadeholt O; Schmalzing M; Geier A
    Clin Rheumatol; 2018 Nov; 37(11):2963-2970. PubMed ID: 30238380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
    Mori S; Fujiyama S
    World J Gastroenterol; 2015 Sep; 21(36):10274-89. PubMed ID: 26420955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
    Ito S
    Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
    Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
    Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
    Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
    Xuan D; Yu Y; Shao L; Wang J; Zhang W; Zou H
    Clin Rheumatol; 2014 Apr; 33(4):577-86. PubMed ID: 24343455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
    Su J; Long L; Zou K
    Clin Rheumatol; 2018 Dec; 37(12):3201-3214. PubMed ID: 29637482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
    Chiu YM; Lai MS; Chan KA
    PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
    Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
    J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
    Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
    Ann Rheum Dis; 2017 Jun; 76(6):1051-1056. PubMed ID: 27934678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.
    Sanz-Bueno J; Vanaclocha F; García-Doval I; Torrado R; Carretero G; Daudén E; Patricia Ruiz-Genao D; Alsina-Gibert MM; Pérez-Zafrilla B; Pérez-Rial G; Rivera R;
    Actas Dermosifiliogr; 2015; 106(6):477-82. PubMed ID: 25776200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.
    Calabrese LH; Zein NN; Vassilopoulos D
    Ann Rheum Dis; 2006 Aug; 65(8):983-9. PubMed ID: 16627542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.
    Kato M; Atsumi T
    Rheumatol Int; 2016 May; 36(5):635-41. PubMed ID: 26573663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
    Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
    Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.